Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Current standard treatment for advanced epithelial ovarian cancer (OC) comprises cytoreductive surgery (CRS) and systemic therapy. Despite initially successful treatment, up to 80% of patients develop recurrent peritoneal disease1. Combining interval CRS with hyperthermic intraperitoneal chemoperfusion (HIPEC) has been shown to lower the risk of peritoneal recurrence2.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
